Study on Personalizing Durvalumab Treatment Duration Using Circulating Tumor DNA for Stage III Non-Small Cell Lung Cancer
Sponsor: Indiana University
ClinicalTrials ID:NCT05757843
This clinical trial is exploring a new way to personalize treatment for patients with stage III non-small cell lung cancer (NSCLC) by using circulating tumor DNA (ctDNA) to decide how long they should receive the drug Durvalumab after initial therapy.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The aim of this study is to use circulating tumor DNA (ctDNA) to help tailor the treatment plan for patients with stage III non-small cell lung cancer (NSCLC). By analyzing ctDNA, doctors hope to determine which patients need longer treatment with Durvalumab and which ones might not need as much. This approach could help avoid unnecessary treatment for those who are already responding well to initial therapy and identify those who might need different strategies early on.
Description
This study focuses on using circulating tumor DNA (ctDNA) to personalize the duration of Durvalumab treatment for patients with stage III non-small cell lung cancer (NSCLC). The goal is to move towards a treatment approach based on specific markers in the blood, rather than just relying on clinical or imaging evidence of the disease. By doing this, the study aims to identify patients who might not need extended cycles of Durvalumab if they are already responding well to initial chemoradiation therapy (CRT). It also seeks to find patients who may not benefit from the standard consolidation therapy early in their treatment, allowing for alternative strategies to be tested when the tumor burden is still low. This personalized approach could help optimize treatment plans and improve outcomes for patients.
Eligibility Criteria
Inclusion Criteria
- Age 18 years or older
- Able to provide written consent and authorization for health information use
- Have inoperable or unresectable stage III NSCLC and are planning to receive or are currently receiving chemoradiation therapy (CRT) followed by Durvalumab
- Must have tissue available for ctDNA testing, either fresh or previously collected
Exclusion Criteria
- Unwilling to provide tissue and blood samples for ctDNA testing
- Have conditions that prevent treatment with CRT and/or Durvalumab
- Have any other active cancer, except for certain types of skin cancer like squamous cell or basal cell cancer
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.